Docket #: S12-133

Novel Protocol For Generation of Cardiac Progenitor Cells and Cardiomyocytes from iPSCs

For the application of human pluripotent stem cell-derived cardiomyocytes in drug discovery, cardiotoxicity testing, disease modeling, and regenerative medicine large numbers of cells need to be derived from a variety of cell lines in a defined, reproducible and cost-efficient manner.

Researchers at Stanford's School of Medicine have developed a technique that enables the differentiation of human pluripotent stem cells to cardiomyocytes with high purity (>85% TNNT2+), efficiency and reproducibility. This technique has been demonstrated to function in a wide variety of hiPSC lines.

Applications

- **Cardiotoxicity Testing**
- Drug testing
- Disease Modeling
- Regenerative Medicine

Advantages

- **High Yield**
- Low Cost
- Reproducibility

Publications

- Published International Patent Application WO 2014078414 A1

Patents

- Published Application: 20140134733
- Issued: 9,234,176 (USA)

Innovators

- Paul Burridge
- Joseph Wu
- Robert Robbins

Licensing Contact

Kimberly Griffin

Technology Licensing and Strategic Alliances Manager

Email